First cell-based flu vaccine listed on NIP ahead of 2024 season
The new quadrivalent vaccine will be available for patients at high risk of complications.
A cell-based quadrivalent flu vaccine will be available on the National Immunisation Program for the first time this year for patients at higher risk of complications from influenza.
From 1 March, Aboriginal and Torres Strait Islander people aged 5-64; pregnant women; and patients aged 5-64 with co-existing conditions, including diabetes, chronic renal failure, heart disease and chronic respiratory or neurological conditions, can get CSL Seqirus’ Flucelvax Quad for free.
